ETON — Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q3 product revenue reached $22.5 million, a 129% increase year-over-year and a 19% increase sequentially. This marks the 19th consecutive quarter of sequential revenue growth.
• Adjusted EBITDA: Reported at $2.9 million, up from $2.0 million in Q3 2024, although impacted by nonrecurring costs related to INCRELEX.
• Net Loss: The company reported a net loss of $1.9 million, compared to a net income of $0.6 million in the prior year. Non-GAAP net income was $1.5 million, down from $1.9 million year-over-year.
• Cash Position: Eton ended the quarter with $37.1 million in cash and generated $12 million in operating cash flow.

2. Strategic Updates and Business Highlights

• Product Performance: Significant revenue contributions came from ALKINDI SPRINKLE, Carglumic Acid, and newly acquired products INCRELEX and GALZIN. INCRELEX has shown strong growth, with active patient counts tracking ahead of expectations.
• Sales Strategy: The sales force was split to enhance focus on pediatric endocrinology, contributing to ALKINDI's growth. The company is also working on a new formulation of KHINDIVI to expand its market.
• Regulatory Developments: Eton submitted an NDA for ET-600, an oral solution for central diabetes insipidus, with a PDUFA date set for February 25, 2026. The company is also pursuing label harmonization for INCRELEX to potentially increase its market opportunity significantly.

3. Forward Guidance and Outlook

• Q4 Expectations: Eton anticipates continued sequential revenue growth but notes that some revenue from INCRELEX-related sales may not recur, potentially leading to flat or slightly declining total product sales in Q4.
• Long-term Growth: The company expects strong growth from its existing products and new launches, with an optimistic outlook for 2026, including continued revenue growth and margin expansion.

4. Bad News, Challenges, or Points of Concern

• Patient Count Dynamics: INCRELEX's net active patient count remained flat due to aging out of patients, which is expected but poses a challenge for sustained growth.
• Gross Margins: Adjusted gross margin was 45%, down from 64% year-over-year, impacted by costs associated with INCRELEX's transition. However, a recovery to approximately 70% is expected in Q4.
• Market Awareness: There is a noted low level of awareness for GALZIN, which presents a challenge but also an opportunity for growth as the company increases educational efforts.

5. Notable Q&A Insights

• INCRELEX Patient Dynamics: The primary reason for patient discontinuation is aging out rather than dissatisfaction with the product. The company aims to improve early diagnosis and treatment initiation to extend patient duration on therapy.
• Future Growth Projections: While the company refrained from providing specific revenue guidance for 2026, it expressed confidence in continued growth across its portfolio and potential acquisitions to enhance its product offerings.
• Business Development: Eton is in late-stage discussions for potential acquisitions of ultra-rare disease products, which could add significant revenue in the coming years.

Overall, Eton Pharmaceuticals demonstrated strong financial performance in Q3 2025, with strategic initiatives aimed at sustaining growth and addressing market challenges. The company remains optimistic about its future prospects, despite some headwinds related to patient dynamics and market awareness.